Safety profile of the proton-pump inhibitors

Reilly, Joseph

doi:10.1093/ajhp/56.suppl_4.s11

Cited by 78 publications

(48 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although PPIs are commonly prescribed and have been found to have a low rate of adverse effects, there are recent reports showing that long-term recipients experience various complications, such as pneumonia, Clostridium difficile infection, and collagenous colitis, as well as malabsorption of vitamin B12, Mg, and Ca10 11 12 23. Alternatively, SIBO is also considered to occur in patients receiving PPIs 13, as that was detected in 50 % of affected patients as compared to 6 % of healthy control subjects in a previous study 14.…”

Section: Discussionmentioning

confidence: 99%

Proton pump inhibitor is a risk factor for recurrence of common bile duct stones after endoscopic sphincterotomy – propensity score matching analysis

et al. 2017

View full text Add to dashboard Cite

Background and study aims Recurrence of common bile duct stones (CBDS) in patients treated with endoscopic sphincterotomy (ES) can lead to deterioration in their quality of life. Although the pathology and related factors are unclear, we speculated that proton pump inhibiter (PPI) administration increases the risk of CBDS recurrence by altering the bacterial mixture in the bile duct. Patients and methods The primary endpoint of this retrospective study was recurrence-free period. Several independent variables considered to have a relationship with CBDS recurrence including PPI use were analyzed using a COX proportional hazard model, with potential risk factors then evaluated by propensity score matching analysis. Results A total of 219 patients were analyzed, with CBDS recurrence found in 44. Analysis of variables using a COX proportional hazard model demonstrated that use of PPIs and ursodeoxycholic acid (UDCA), as well as the presence of periampullary diverticula (PD) each had a hazard ratio (HR) value greater than 1 (HR 2.2, P = 0.007; HR 2.0, P = 0.02; HR 1.9, P = 0.07; respectively). Furthermore, propensity score matching analysis revealed that the mean recurrence-free period in the oral PPI cohort was significantly shorter as compared with the non-PPI cohort (1613 vs. 2587 days, P = 0.014). In contrast, neither UDCA administration nor PD presence was found to be a significant factor in that analysis (1557 vs. 1654 days, P = 0.508; 1169 vs. 2011 days, P = 0.121; respectively). Conclusion Our results showed that oral PPI administration is a risk factor for CBDS recurrence in patients who undergo ES.

show abstract

Section: Discussionmentioning

confidence: 99%

Proton pump inhibitor is a risk factor for recurrence of common bile duct stones after endoscopic sphincterotomy – propensity score matching analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…It has been suggested that PPI therapy may confer a risk of developing C. difficile-associated diarrhoea [3]. PPI therapy may also mask features of gastric cancer [12,13]. PPI use is also associated with higher risk of developing CAP and hip fracture.…”

Section: Discussionmentioning

confidence: 99%

Inappropriate use of proton pump inhibitors

Molloy

Molloy²,

O’Loughlin³

et al. 2009

Ir J Med Sci

View full text Add to dashboard Cite

show abstract

“…1 Since their introduction, the prevalence of PPI use has increased substantially, 2,3 and global total cost expenditure on PPIs ranks second only to statins. 4 PPIs are well-tolerated, having few acute side effects, 5 and are now available without prescription in many countries. 6 However, observational studies of PPI use have reported associations with several adverse outcomes including community acquired pneumonia, 7 hip fracture, 8,9 hyomagnesemia, 10 chronic kidney disease, 11 and Clostridium difficile -associated diarrhea.…”

Section: Introductionmentioning

confidence: 99%

Association Between Proton Pump Inhibitor Use and Cognitive Function in Women

et al. 2017

View full text Add to dashboard Cite

Background & Aims Studies have reported associations between proton pump inhibitor (PPI) use and dementia. However, data are lacking on long-term PPI use and cognitive function. We therefore examined associations between PPI use and performance in tests of cognitive function. Because of shared clinical indications, we examined associations for H2 receptor antagonists (H2RAs) as a secondary aim. Methods We used prospectively collected data on medication use and other potential risk factors from 13,864 participants in the Nurses’ Health Study II who had completed a self-administered computerized neuropsychological test battery. Multi-variable linear regression models were used to examine associations between medication use and composite scores of psychomotor speed and attention, learning and working memory, and overall cognition. Results We observed a modest association between duration of PPI use and scores for psychomotor speed and attention (mean score difference for PPI use of 9–14 yrs vs never users, −0.06; 95% CI, −0.11 to 0.00; Ptrend = .03). After controlling for H2RA use, the magnitude of this score difference was attenuated. Among individuals who did not regularly use PPIs, duration of H2RA use was associated with poorer cognitive scores, with the strongest association apparent for learning and working memory (mean score difference for H2RA users of 9–14 years vs never users, −0.20; 95% CI, −0.32 to −0.08; Ptrend < .001). Conclusions In an analysis of data from the Nurses’ Health Study II, we did not observe a convincing association between PPI use and cognitive function. Our data do not support the suggestion that PPI use increases dementia risk. Since our primary hypothesis related to PPI use, our findings for H2RAs should be interpreted with caution.

show abstract

Safety profile of the proton-pump inhibitors

Cited by 78 publications

References 0 publications

Proton pump inhibitor is a risk factor for recurrence of common bile duct stones after endoscopic sphincterotomy – propensity score matching analysis

Proton pump inhibitor is a risk factor for recurrence of common bile duct stones after endoscopic sphincterotomy – propensity score matching analysis

Inappropriate use of proton pump inhibitors

Association Between Proton Pump Inhibitor Use and Cognitive Function in Women

Contact Info

Product

Resources

About